ストックスクリーナーアプリを入手
16.77
0.83%
-0.14
アフターアワーズ：
16.77
前日終値:
$16.91
開ける：
$16.99
24時間の取引高:
406.27K
Relative Volume:
0.89
時価総額：
$5.98B
収益：
$5.21B
当期純損益:
$-211.00M
株価収益率:
-27.14
EPS:
-0.6179
ネットキャッシュフロー:
$861.30K
1週間 パフォーマンス:
+3.01%
1か月 パフォーマンス:
-2.27%
6か月 パフォーマンス:
+3.45%
1年 パフォーマンス:
+24.22%
1日の値動き範囲:
$16.55
$17.11
1週間の範囲:
$15.64
$17.11
52週間の値動き範囲:
$13.53
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
Compare BLCO vs ISRG, BDX, ALC, MDLN, RMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
16.77 | 5.80B | 5.21B | -211.00M | 861.30K | -0.6179 |
ISRG
Intuitive Surgical Inc
|
375.41 | 127.84B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
170.21 | 43.79B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
70.21 | 32.81B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
40.47 | 33.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
215.19 | 29.46B | 5.54B | 1.52B | 1.74B | 10.37 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-12-11 | アップグレード | Citigroup | Neutral → Buy |
| 2025-12-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | 開始されました | Goldman | Neutral |
| 2025-05-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-03-28 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-12-02 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-07-10 | 開始されました | Raymond James | Outperform |
| 2024-05-06 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-12-12 | 開始されました | Stifel | Hold |
| 2023-10-03 | 再開されました | Evercore ISI | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-03-09 | 開始されました | Needham | Hold |
| 2022-12-21 | 開始されました | Barclays | Equal Weight |
| 2022-09-12 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-06-24 | 開始されました | Evercore ISI | Outperform |
| 2022-06-06 | 開始されました | Citigroup | Buy |
| 2022-05-31 | 開始されました | Deutsche Bank | Hold |
| 2022-05-31 | 開始されました | Goldman | Neutral |
| 2022-05-31 | 開始されました | Guggenheim | Buy |
| 2022-05-31 | 開始されました | JP Morgan | Neutral |
| 2022-05-31 | 開始されました | Jefferies | Buy |
| 2022-05-31 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 開始されました | Wells Fargo | Overweight |
| 2022-05-11 | 開始されました | Cowen | Outperform |
すべてを表示
Bausch Lomb Corp (BLCO) 最新ニュース
Bausch + Lomb earnings up next: Can growth offset pipeline loss? - Investing.com
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
Bausch + Lomb Corp (BLCO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BLCO|Bausch + Lomb Corp|Price:16.260|Chg%:+0.090 - TradingKey
Bausch + Lomb Corporation Revenue Breakdown – MUN:S2L - TradingView
Bausch + Lomb Corp (BLCO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Investor Outlook: Bausch + Lomb Corporation (BLCO) Eyes 12% Upside Potential Amid Steady Growth - DirectorsTalk Interviews
Bausch + Lomb Corp (BLCO) Balance Sheet - TradingKey
Bausch + Lomb Corp (BLCO) Cash Flow - TradingKey
Bausch + Lomb Corp (BLCO) Income Statement - TradingKey
Bausch + Lomb Corp (BLCO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bausch + Lomb Corp (BLCO) Institutional Confidence - TradingKey
BLCO|Bausch + Lomb Corp|Price:16.170|Chg%:+0.210 - TradingKey
Bausch + Lomb Corporation (BLCO) Gets a Hold from Wells Fargo - The Globe and Mail
BLCO Forecast — Price Target — Prediction for 2027 - TradingView
3 Reasons to Avoid BLCO and 1 Stock to Buy Instead - Yahoo Finance
Bausch + Lomb launches EyeGility preloaded IOL delivery system in US - Ophthalmology Times Europe
Bausch + Lomb launches EyeGility inserter for enVista IOLs in the US - MSN
Bausch Health Companies stock hits 52-week low at $4.56 By Investing.com - Investing.com South Africa
Bausch Health Companies stock hits 52-week low at $4.56 - Investing.com
Bausch + Lomb launches EyeGility Inserter to streamline cataract lens delivery in US - Indian Pharma Post
BHC5652799 Bond Profile — Key Metrics - TradingView
Bausch + Lomb Launches the EyeGility Inserter Preloaded IOL Delivery System - VisionMonday.com
Bausch + Lomb launches AI-powered digital health platform By Investing.com - Investing.com Nigeria
Bausch + Lomb's Prescription Drug Growth Could Support Q2 Results, RBC Says - Moomoo
RBC Capital Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Bausch + Lomb Launches EyeGility Inserter for enVista IOLs in the U.S. - Yahoo Finance
Bausch + Lomb Corporation (BLCO) Stock Analysis: Eyeing A Potential 11.54% Upside - DirectorsTalk Interviews
Bausch + Lomb (BLCO) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure - Stocktwits
(BLCO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Intellia Therapeutics (NTLA) - The Globe and Mail
Bausch + Lomb launches EyeGility IOL delivery system in U.S. By Investing.com - Investing.com Australia
Bausch + Lomb's BL1107 falls short in phase 2 glaucoma trial, redirects program toward geographic atrophy implant - Ophthalmology Times Europe
Bausch + Lomb Launches EyeGility Inserter Preloaded IOL Delivery System In The United States - marketscreener.com
Bausch + Lomb launches EyeGility IOL delivery system in U.S. - Investing.com
Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States - Business Wire
Goldman Sachs Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $21 - Moomoo
(BLCO) Equity Market Report (BLCO:CA) - Stock Traders Daily
Bausch + Lomb's BL1107 fails primary end point in Phase 2 glaucoma trial - Optometry Times
Ophthalmology Devices Market Report Released, Includes - GlobeNewswire
Ophthalmology Devices Market Report Released, Includes Profiles of EssilorLuxottica, Alcon, Bausch + Lomb, and 20 Others - Yahoo Finance UK
Bausch + Lomb Corporation (BLCO) Stock Analysis: Examining a Healthcare Leader with 11.68% Potential Upside - DirectorsTalk Interviews
(BLCO) Technical Pivots with Risk Controls (BLCO:CA) - Stock Traders Daily
Bausch + Lomb abandons glaucoma drops after phase 2 failure - MSN
Bausch + Lomb ditches BL1107 in glaucoma after trial miss - The Pharma Letter
Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today - Yahoo Finance
Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus - Benzinga
Bausch + Lomb Introduces Orphia, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care - marketscreener.com
Price to earnings forward of Bausch + Lomb Corporation – NYSE:BLCO - TradingView
Price to sales forward of Bausch + Lomb Corporation – NYSE:BLCO - TradingView
Bausch Lomb Corp (BLCO) 財務データ
収益
当期純利益
現金流量
EPS
Bausch Lomb Corp (BLCO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Eldessouky Sam | EVP and CFO |
Mar 06 '26 |
Buy |
17.13 |
4,000 |
68,520 |
403,130 |
| SAUNDERS BRENT L | CEO and Chairman of the Board |
Mar 06 '26 |
Buy |
17.14 |
14,700 |
251,958 |
966,575 |
| Ross Thomas W. Sr. | Director |
Mar 03 '26 |
Buy |
17.68 |
4,500 |
79,556 |
64,891 |
| Alfonso Eduardo | Director |
Mar 02 '26 |
Buy |
17.90 |
4,300 |
76,970 |
9,555 |
| VON ESCHENBACH ANDREW C. | Director |
Feb 27 '26 |
Buy |
18.30 |
4,364 |
79,883 |
66,450 |
| COLLIS STEVEN H | Director |
Feb 23 '26 |
Buy |
17.81 |
15,000 |
267,150 |
20,255 |
| ROBERTSON RUSSEL C | Director |
Feb 20 '26 |
Buy |
17.90 |
4,400 |
78,760 |
72,407 |
| Ling Karen | Director |
Feb 19 '26 |
Buy |
17.74 |
4,000 |
70,968 |
41,676 |
2.24%
大文字化:
|
ボリューム (24 時間):